Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Pulmonary homograft stenosis in the Ross procedure: Incidence, clinical impact and predictors in long-term follow-up

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Pardo Gonzalez, Laura Reina Sofia Univ Hosp, Dept Cardiol, Cordoba, Spain; Ruiz Ortiz, Martin Reina Sofia Univ Hosp, Dept Cardiol, Cordoba, Spain; Delgado, Monica Reina Sofia Univ Hosp, Dept Cardiol, Cordoba, Spain; Mesa, Dolores Reina Sofia Univ Hosp, Dept Cardiol, Cordoba, Spain; Rodriguez, Sara Reina Sofia Univ Hosp, Dept Cardiol, Cordoba, Spain; Hidalgo, Francisco J. Reina Sofia Univ Hosp, Dept Cardiol, Cordoba, Spain; Suarez de Lezo, Jose Reina Sofia Univ Hosp, Dept Cardiol, Cordoba, Spain; Villalba, Rafael Reg Blood Transfus Ctr & Tissue Bank, Cordoba, Spain; Alados, Pedro Reina Sofia Univ Hosp, Dept Cardiovasc Surg, Cordoba, Spain; Casares, Jaime Reina Sofia Univ Hosp, Dept Cardiovasc Surg, Cordoba, Spain
    • Publication Information:
      Elsevier masson, corp off
    • Publication Date:
      2017
    • Collection:
      Sistema Sanitario Público de Andalucía (SSPA): Repositorio
    • Abstract:
      Background. - The Ross procedure is used in the treatment of selected patients with aortic valve disease. Pulmonary graft stenosis can appear in the long-term follow-up after the Ross intervention, but the factors involved and its clinical implications are not fully known. Aim. To describe the incidence, clinical impact and predictors of homograft stenosis and reintervention after the Ross procedure in a prospective series in a tertiary referral hospital.Methods. - From 1997 to 2009, 107 patients underwent the Ross procedure (mean age: 30 +/- 11 years; 69% men; 21 aged 36 mmHg) and surgical or percutaneous homograft reintervention.Results. - After 15 years of follow-up (median: 11 years), echocardiographic and clinical data were available in 91 (85%) and 104 (98%) patients, respectively: 26/91 (29%) patients developed homograft stenosis; 10/104 (10%) patients underwent 13 homograft reintervention procedures (three patients underwent surgical replacement, three received a percutaneous pulmonary valve and one needed stent implantation). The other three patients underwent two consecutive procedures in follow-up; one died because of a procedure-related myocardial infarction. Rates of survival free from homograft stenosis and reintervention at 1, 5 and 10 years were 96%, 82% and 75% and 99%, 94% and 91%, respectively. Paediatric patients had worse survival free from homograft stenosis (hazard ratio [HR] 3.50, 95% confidence interval [CI]: 1.56-7.90; P=0.002), although there were no significant differences regarding reintervention (HR: 2.01, 95% CI: 0.52-7.78; P=0.31). Younger age of homograft donor was also a stenosis predictor (HR: 0.97, 95% CI: 0.94-0.99; P=0.046).Conclusions. - The probabilities of homograft stenosis and reintervention 10 years after the Ross procedure were 29% and 10%, respectively; only one patient had a reintervention-related death. Younger donor and recipient age were associated with a higher rate of stenosis. (C) 2016 Elsevier Masson SAS. All rights reserved.
    • ISSN:
      1875-2136
      1875-2128
    • Relation:
      http://hdl.handle.net/10668/18670; https://doi.org/10.1016/j.acvd.2016.09.008; 403531600003
    • Accession Number:
      10.1016/j.acvd.2016.09.008
    • Online Access:
      https://doi.org/10.1016/j.acvd.2016.09.008
      http://hdl.handle.net/10668/18670
    • Rights:
      open access
    • Accession Number:
      edsbas.42171CA8